Breakthrough T1D awarded a grant to support SAB Biotherapeutics' PRISE-hATG study, which tests SAB-142 in patients with Stage 3 type 1 diabetes diagnosed 100 days to 2 years prior. The study aims to see if SAB-142 can preserve insulin-producing beta cells beyond the early disease stage, potentially expanding treatment options for millions with T1D. SAB-142 is a fully human anti-thymocyte immunoglobulin designed to modulate immune responses and slow disease progression. This trial complements an ongoing Phase 2b study and is co-funded by SAB BIO, highlighting progress toward disease-modifying therapies for T1D.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
